Literature DB >> 31732781

[Unexpectedly high mortality after surgical liver interventions in Germany].

David Krug1, Ralf Hofheinz2, Eleni Gkika3, Thomas Brunner4, Judit Boda-Heggemann5.   

Abstract

Mesh：

Year:  2020        PMID： 31732781     DOI： 10.1007/s00066-019-01547-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

Review 1.  Building a collaboration to improve surgical research through EORTC/ESSO 1409-CLIMB study: A prospective liver metastasis database with an integrated quality assurance program.

Authors:  Carmela Caballero; Susen Burock; Lucia Carrion-Alvarez; Henrik Nilsson; Theo Ruers; Perrine Senellart; Michel Rivoire; Stefan Stattner; Florian Primavesi; Roberto Troisi; Thomas Gruenberger; Jan Heil; Andreas A Schnitzbauer; Nuh N Rahbari; Rutger-Jan Swijnenburg; Hassan Malik; Mladjan Protic; Kozo Kataoka; Murielle Mauer; Michel Ducreux; Graeme Poston; Serge Evrard
Journal:  Eur J Surg Oncol       Date:  2019-05-30       Impact factor: 4.424

2.  Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma.

Authors:  Alexis Bujold; Christine A Massey; John J Kim; James Brierley; Charles Cho; Rebecca K S Wong; Rob E Dinniwell; Zahra Kassam; Jolie Ringash; Bernard Cummings; Jenna Sykes; Morris Sherman; Jennifer J Knox; Laura A Dawson
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

3.  Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Thomas B Brunner; Oliver Blanck; Victor Lewitzki; Nasrin Abbasi-Senger; Felix Momm; Oliver Riesterer; Marciana Nona Duma; Stefan Wachter; Wolfgang Baus; Sabine Gerum; Matthias Guckenberger; Eleni Gkika
Journal:  Radiother Oncol       Date:  2018-12-20       Impact factor: 6.280

4.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

5.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

Authors:  Daniel R Gomez; Chad Tang; Jianjun Zhang; George R Blumenschein; Mike Hernandez; J Jack Lee; Rong Ye; David A Palma; Alexander V Louie; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; James W Welsh; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Anne S Tsao; Boris Sepesi; Stephen G Swisher; John V Heymach
Journal:  J Clin Oncol       Date:  2019-05-08       Impact factor: 44.544

6.  Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.

Authors:  Eleni Gkika; Lukas Hallauer; Simon Kirste; Sonja Adebahr; Nico Bartl; Hannes Philipp Neeff; Ralph Fritsch; Volker Brass; Ursula Nestle; Anca Ligia Grosu; Thomas Baptist Brunner
Journal:  BMC Cancer       Date:  2017-11-21       Impact factor: 4.430

7.  The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases.

Authors:  N Andratschke; H Alheid; M Allgäuer; G Becker; O Blanck; J Boda-Heggemann; T Brunner; M Duma; S Gerum; M Guckenberger; G Hildebrandt; R J Klement; V Lewitzki; C Ostheimer; A Papachristofilou; C Petersen; T Schneider; R Semrau; S Wachter; D Habermehl
Journal:  BMC Cancer       Date:  2018-03-13       Impact factor: 4.430

Review 8.  Laparoscopic Hepatectomy for Colorectal Liver Metastases: The Current State of the Art.

Authors:  Aali J Sheen; Saurabh Jamdar; Ajith K Siriwardena
Journal:  Front Oncol       Date:  2019-05-31       Impact factor: 6.244

9.  The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases.

Authors:  Rainer J Klement; N Abbasi-Senger; S Adebahr; H Alheid; M Allgaeuer; G Becker; O Blanck; J Boda-Heggemann; T Brunner; M Duma; M J Eble; I Ernst; S Gerum; D Habermehl; P Hass; C Henkenberens; G Hildebrandt; D Imhoff; H Kahl; N D Klass; R Krempien; V Lewitzki; F Lohaus; C Ostheimer; A Papachristofilou; C Petersen; J Rieber; T Schneider; E Schrade; R Semrau; S Wachter; A Wittig; M Guckenberger; N Andratschke
Journal:  BMC Cancer       Date:  2019-02-26       Impact factor: 4.430

10.  Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.

Authors:  Theo Ruers; Frits Van Coevorden; Cornelis J A Punt; Jean-Pierre E N Pierie; Inne Borel-Rinkes; Jonathan A Ledermann; Graeme Poston; Wolf Bechstein; Marie-Ange Lentz; Murielle Mauer; Gunnar Folprecht; Eric Van Cutsem; Michel Ducreux; Bernard Nordlinger
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 11.816
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.